Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 3/20 | 0.63 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.63 |
| ▸ | DRD3 | P35462 | 2/20 | 0.63 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.63 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.63 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.63 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.63 |
| ▸ | DRD1 | P21728 | 1/20 | 0.63 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.63 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.63 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.63 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.63 |
| ▸ | HTR7 | P34969 | 12/20 | 0.60 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.51 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.46 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12715448 | 0.84 | HTR7 (0.67) | HTR1AADRA2ADRD3ADRA1AABCB11 | |
| SCHEMBL12319206 | 0.84 | HTR7 (0.56) | HTR1AADRA2ADRD3ADRA1AABCB11 | |
| SCHEMBL27246583 | 0.83 | HTR7 (0.68) | HTR1AADRA2ADRD3ADRA1AABCB11 | |
| SCHEMBL7552254 | 0.81 | HTR1A (0.70) | HTR1AADRA2ADRD3ADRA1AABCB11 | |
| SCHEMBL7552451 | 0.81 | HTR1A (0.70) | HTR1AADRA2ADRD3ADRA1AABCB11 | |
| SCHEMBL678268 | 0.78 | HTR1A (0.78) | HTR1AADRA2ADRD3ADRA1AABCB11 | |
| Flibanserin SCHEMBL30249132 | 0.77 | HTR1A (1.00) | HTR1AADRA2ADRD3ADRA1AABCB11 | |
| Flibanserin SCHEMBL29399513 | 0.77 | HTR1A (1.00) | HTR1AADRA2ADRD3ADRA1AABCB11 | |
| Flibanserin SCHEMBL247579 | 0.77 | HTR1A (1.00) | HTR1AADRA2ADRD3ADRA1AABCB11 | |
| SCHEMBL12715437 | 0.77 | HTR1A (0.70) | HTR1AADRA2ADRD3ADRA1AABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7923449-B2 | Using 1-(2-(3-trifluoromethylphenyl)piperazin-1-yl)ethyl)2,3-dihydro-1H-benzimidazol-2-one | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-04-12 | — | — | US | disclosed |
| US-20090176698-A1 | Benzimidazolone Derivatives for the Treatment of Urinary Incontinence | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-07-09 | — | — | US | disclosed |
| US-20090176698-A1 | Benzimidazolone Derivatives for the Treatment of Urinary Incontinence | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-07-09 | — | — | US | disclosed |
| US-20080242679-A1 | Benzimidazolone Derivatives For the Treatment of Premenstrual and Other Female Sexual Disorders | VRX HOLDCO LLC | 2008-10-02 | — | — | US | disclosed |
| WO-2008061968-A1 | BENZIMIDAZOLONE DERIVATES IN THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-05-29 | — | — | WO | disclosed |
| WO-2007096300-A1 | BENZIMIDAZOLONE DERIVATIVES FOR THE TREATMENT OF URINARY INCONTINENCE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-08-30 | — | — | WO | disclosed |
| WO-2007048803-A1 | BENZIMIDAZOLONE DERIVATIVES FOR THE TREATMENT OF PREMENSTRUAL AND OTHER FEMALE SEXUAL DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-03 | — | — | WO | disclosed |
| WO-2007048801-A2 | SEXUAL DESIRE ENHANCING MEDICAMENTS COMPRISING BENZIMIDAZOLONE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-03 | — | — | WO | disclosed |
| EP-1218352-A1 | BENZIMIDAZOLONE DERIVATIVES HAVING MIXED SEROTONINE AND DOPAMINE RECEPTORS AFFINITY | BOEHRINGER INGELHEIM ITALIA S.p.A. (IT) | 2002-07-03 | — | — | EP | disclosed |
| US-6281218-B1 | USEFUL IN THE TREATMENT OF CNS DISORDERS. | INGELHEIM ITALIA S.P.A. (IT) | 2001-08-28 | — | — | US | disclosed |
| WO-2001021593-A1 | NEW BENZIMIDAZOLONE DERIVATIVES HAVING MIXED SEROTONINE AND DOPAMINE RECEPTORS AFFINITY | BOEHRINGER INGELHEIM ITALIA S.P.A. (IT) | 2001-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176698-A1 | Benzimidazolone Derivatives for the Treatment of Urinary Incontinence | HRH2, AVPR2, HRH1 | HTR1A 765/4885ADRA2A 296/4885DRD3 1608/4885 |
| US-20080242679-A1 | Benzimidazolone Derivatives For the Treatment of Premenstrual and Other Female Sexual Disorders | GABBR1, CYP19A1, GABBR2 | HTR1A 195/4885ADRA2A 467/4885DRD3 230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.